#Pfizer stock movements

[waledxman123]

Pfizer and Tilray: Contrasting Stock Movements Spark Investor Interest

The financial and investment landscape recently spotlighted significant developments in the stock movements of Pfizer Inc. (NYSE:PFE) and Tilray Brands Inc. (NASDAQ:TLRY). These activities have shed light on the evolving dynamics in the pharmaceutical and cannabis industries, drawing attention from institutional and individual investors alike.

Pfizer: A Mixed Bag of Investor Sentiment

Acquisition by Rep. Laurel M. Lee Rep. Laurel M. Lee disclosed a recent acquisition of Pfizer stock, signaling confidence in the pharmaceutical giant’s long-term prospects. Pfizer, a household name due to its role in combatting COVID-19, continues to leverage its expansive portfolio beyond vaccines. Current endeavors focus on oncology, rare diseases, and innovations in antiviral treatments. This move by Lee highlights a potential faith in Pfizer’s strategic pivots and innovation-focused future, despite recent challenges in revenue growth​

read more in google news

3. Pfizer’s Broader Challenges Despite these contrasting stock activities, Pfizer’s fundamentals remain strong. With a robust pipeline of drugs, the company is poised to capitalize on innovations in gene therapy and precision medicine. Additionally, its strategic acquisitions aim to offset losses from expiring patents. However, the road to sustained growth appears challenging, given the current macroeconomic environment and evolving healthcare demands.

read more in google news

Tilray: Strategic Diversification Amid Industry Volatility

Tilray’s Stock Performance Tilray Brands, a global leader in cannabis and consumer-packaged goods, has witnessed significant investor interest due to its strategic initiatives. The company’s stock has been influenced by its aggressive expansion into non-cannabis sectors, including beverages and wellness products. These moves reflect Tilray’s efforts to weather the volatility of the cannabis market and regulatory hurdles in the United States and beyondough Diversification** Tilray’s ability to adapt has been pivotal. The company has strengthened its foothold by acquiring prominent beverage brands and expanding into THC and CBD-infused products. Its partnerships across North America and Europe underscore its vision for long-term growth in a market where legalization trends are gaining momentum. Tilray’s performance has also been bolstered by its entry into consumer-packaged goods, providing a hedge against the slower-than-expected legalization of recreational cannabis in the U.S. .

3. Industrynges Despite these efforts, Tilray faces headwinds. Oversupply issues in the cannabis market, fluctuating product prices, and fragmented regulations remain significant barriers. While the company is capitalizing on its international footprint, the U.S. remains a critical market for future growth. Investors are closely monitoring developments in federal legalization efforts, which could provide a substantial tailwind for Tilray’s ambitions.

read more in google news

Investor Takeaways: Contrasting Dynamics in Key Sectors

The contrasting approaches to Pfizer and Tilray stocks highlight broader themes in their respective industries:

Pharmaceuticals: Pfizer’s stock movements reflect both optimism about its innovative pipeline and concerns about its near-term revenue challenges. The company’s ability to execute its post-pandemic strategy will be critical to regaining investor confidence.

Cannabis: Tilray’s story underscores the importance of strategic diversification and adaptability in a nascent yet volatile industry. While challenges persist, the company’s proactive steps toward market expansion position it well for future growth.

These developments underscore the complexity of investing in dynamic, highly regulated sectors where innovation, strategy, and market sentiment intersect.

[coochiequeens]

This article is from last year but since I posted about detransitioners earlier this week I think this is relevant

Testosterone Therapy in a Transgender Male Patient as a cause of Acute Ischemic Stroke (P2-5.011)

Christina Tan, Lauren Kim Sing, Ron Danziger, Alex Aw, Chae Kim, Stephen Avila, Vilakshan Alambyan, Angud Mehdi, Michael Gezalian, Maranatha Ayodele, and Shahed ToossiAuthors Info & Affiliations

April 25, 2023 issue

Objective:

To share an intriguing case of a young transgender male patient receiving testosterone therapy who developed locked-in syndrome due to an acute ischemic stroke and to highlight potential risk factors for stroke in the LGBTQI+ community

Background:

There are many studies identifying risk factors for stroke in racially and ethnically diverse populations. However, there is little existing data for stroke risk factors in the LGBTQI+ community. Prior research has shown testosterone therapy in cis-gender men with initially low levels of testosterone increases the risk of stroke, especially in the first 2 years of use1. While testosterone therapy has been shown to increase the risk of venous thrombosis, its role in arterial thrombosis is unclear2. A proposed mechanism for thrombosis with testosterone replacement includes erythrocytosis, but the potential contribution of an independent pro-coagulant effect is yet to be determined3.

Design/Methods:

Literature review and case report.

Results:

An otherwise healthy 23-year-old transgender male on one year of testosterone therapy presented in an obtunded state. Examination revealed complete quadriplegia with sparing of vertical eye movements, consistent with locked-in syndrome. Imaging revealed complete occlusion of the basilar artery with distal reconstitution at the superior cerebellar arteries, and a large bilateral ischemic infarct of the pons. Computed tomography angiography did not demonstrate other large vessel disease or structural vascular abnormalities. Unfortunately, the patient was out of the time window for any acute stroke interventions. A hypercoagulable workup was performed but results were unrevealing and hematocrit was normal. Further investigation with transthoracic echocardiogram, transesophageal echocardiogram, and telemetry were negative for thrombus, patent foramen ovale, and atrial fibrillation.

Conclusions:

Acute ischemic stroke may be an under recognized complication of testosterone therapy in transgender males independent of degree of erythrocytosis. Further research is needed to establish a safety profile of testosterone therapy in this understudied population.

Disclosure: Dr. Tan has nothing to disclose. Mrs. Kim Sing has nothing to disclose. Dr. Danziger has nothing to disclose. Mr. AW has nothing to disclose. Dr. Kim has nothing to disclose. Dr. Avila has nothing to disclose. Dr. Alambyan has stock in Teleflex. Dr. Alambyan has stock in Natera. Dr. Alambyan has stock in Labcorp. Dr. Alambyan has stock in Veracyte. Dr. Alambyan has stock in Vicarious Surgical. Dr. Alambyan has stock in Unity Biotechnology. Dr. Alambyan has stock in Scynexis. Dr. Alambyan has stock in Stryker. Dr. Alambyan has stock in Eli Lilly. Dr. Alambyan has stock in DaVita. Dr. Alambyan has stock in Invitae. Dr. Alambyan has stock in Pfizer. Dr. Alambyan has stock in Bristol-Myers Squibb. Dr. Alambyan has stock in Johnson and Johnson. Dr. Alambyan has stock in Merck. Dr. Alambyan has stock in Medtronic. Dr. Alambyan has stock in AbbVie. The institution of Dr. Alambyan has received research support from Albert Einstein Healthcare Network. Dr. Mehdi has nothing to disclose. Dr. Gezalian has nothing to disclose. Dr. Ayodele has nothing to disclose. Dr. Toossi has nothing to disclose.

[poonamcmi]

Over The Counter Pain Medication market will grow at highest pace owing to rising geriatric population

The over the counter pain medication market consists of non-prescription drugs used to relieve pain such as headaches, muscle pains, backaches, toothaches, colds, menstrual cramps and arthritis. These drugs provide temporary relief from pain and include analgesics like paracetamol and non-steroidal anti-inflammatory drugs such as ibuprofen and aspirin. Non-prescription pain medications are widely available as tablets, capsules and liquids in retail pharmacies and online stores, providing convenience to consumers. With growing aging population suffering from arthritis and other joint pains, the demand for these medications is increasing rapidly.

The Global Over The Counter Pain Medication Market is estimated to be valued at US$ 27.12 Bn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Over The Counter Pain Medication market include Johnson & Johnson, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Sanofi S.A., Reckitt Benckiser Group plc, Novartis AG, Perrigo Company plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Lupin Limited, Aurobindo Pharma Limited. The dominance of these key players is attributed to their diverse product portfolio and strong global distribution network.

Over The Counter Pain Medication Market Demand rapidly owing to increasing incidences of headache, joint pains and menstrual problems across major countries. Self-medication has become popular as consumers frequently purchase these drugs for quick relief from minor pains without doctor's prescription.

Technological advancements are leading to development of innovative drug delivery systems for over the counter pain medications such as fast-dissolving oral thin films and gels providing pain relief more quickly. Development of combination drugs offering relief from multiple symptoms with a single drug is another key trend observed in this market. Market Trends Sustained release formulations are gaining popularity in the over the counter pain medication market. These ensure drugs remain effective for longer duration, releasing medicine slowly into the body. For example, Advil has introduced extended release gels providing all-day relief from pain.

Combination drugs offering relief from pain as well as symptoms like cold, cough and fever are witnessing strong demand. Consumers prefer single drugs treating multiple conditions. Manufacturers are developing combination pills accordingly to increase sales.

Market Opportunities The rising geriatric population suffering from arthritis and joint pains worldwide presents significant growth opportunities. Around 100 million US adults suffer from arthritis currently and the number is projected to rise to 130 million by 2060.

Online pharmacies are emerging as an important sales channel for over the counter pain medications. Expanding e-commerce and increasing preference of consumers to shop online from the convenience of their homes will drive future revenues in this distribution segment.

Impact of COVID-19 on Over The Counter Pain Medication Market Size And Trends  The COVID-19 pandemic has immensely impacted the growth of the over the counter pain medication market globally. During the initial phase of the pandemic, there was a sharp surge in demand for pain relieving drugs like paracetamol, ibuprofen etc. as people stocked up medicines fearing potential shortages. This led to a significant spike in sales revenues for OTC pain medication manufacturers in 2020. However, as the pandemic prolonged, lockdowns imposed worldwide disrupted manufacturing and supply chain operations. Strict movement restrictions made it difficult for companies to transport raw materials and finished drugs. The declining disposable incomes and job losses during the economic downturn also reduced people's spending power which hindered the market growth post-2020.

To overcome resource constraints, companies focused on streamlining production and prioritizing essential medicines. They established alternative sourcing routes and enhanced inventory levels. Digitization of processes helped maintain business continuity. As restrictions eased in 2021-22, market saw a steady recovery backed by mass vaccination drives. Demand revived in retail channels and e-commerce platforms. However, hovering price pressures due to high production costs remain a key challenge. In the coming years, companies need to optimize costs, expand into virtual care solutions and tap opportunities in pain relief for Covid-19 associated symptoms to sustain growth in the post pandemic environment. Geographical Regions with Highest Over The Counter Pain Medication Market Value ​North America has been the largest regional market for over the counter pain medication, accounting for around 40% of global value due to high healthcare spending and self-medication trend. Within North America, the US commands the major share owing to large population size and presence of major manufacturers. Europe holds the second position while Asia Pacific is fastest growing region supported by expanding medical industries, rising health awareness and large patient pool in China and India. Fastest Growing Region in Over The Counter Pain Medication Market Asia Pacific region is poised to witness the fastest growth in the over the counter pain medication market during the forecast period. Factors such as rising middle class disposable incomes, increased spending on healthcare, growing geriatric population susceptible to joint disorders and innovations by local pharmaceutical giants are driving the market growth in Asia Pacific countries. Additionally, self-medication has become more prominent with easier access to OTC drugs via e-retailers and convenience stores. China, India, Japan, South Korea, Indonesia and other Southeast Asian countries offer immense untapped opportunities for OTC painkiller brands seeking to expand in Asia. Get More Insights On, Over The Counter Pain Medication Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[ciolookleaders]

Pfizer (PFE) Stock Analysis and Outlook Ahead of Earnings Report

Source-jacobin.com

Market Performance and Recent Trends

In the latest trading session, Pfizer Stock closed at $26.26, showing a 1% increase from the previous day, outperforming the S&P 500’s 0.87% gain. Concurrently, the Dow rose by 0.67%, and the Nasdaq, dominated by tech stocks, saw an increase of 1.11%. Over the past month, Pfizer shares had incurred a 4.97% loss, while the medical sector faced a 6.67% decline, and the S&P 500 dipped by 3.97%.

Earnings Forecast and Analyst Insights

Investors are eagerly anticipating Pfizer’s upcoming earnings report scheduled for May 1, 2024. Analysts predict an EPS of $0.56, reflecting a 54.47% decrease compared to the same quarter last year. Revenue is estimated to be $13.86 billion, indicating a 24.21% decline year-over-year. Full-year projections suggest earnings of $2.23 per share and revenue of $60.26 billion, translating to increases of 21.2% and 3.01%, respectively, from the prior year.

Analysts have revised their estimates for Pfizer, signaling the dynamic nature of business trends. Positive revisions suggest confidence in the company’s performance and profit-generating capabilities. These adjustments are closely linked to short-term stock movements, with the Zacks Rank providing investors with actionable insights. Currently, Pfizer holds a Zacks Rank of #3 (Hold), with a 0.86% increase in the Zacks Consensus EPS estimate over the last 30 days.

Expert Analysis on Pfizer Stock — $PFE

Valuation Metrics and Industry Ranking

Pfizer’s Forward P/E ratio stands at 11.64, indicating potential undervaluation compared to the industry’s average of 13.89. Furthermore, its PEG ratio of 1.17 suggests a balanced growth outlook, considering the expected earnings growth rate. In contrast, the industry’s average PEG ratio was higher at 1.63. The Large Cap Pharmaceuticals industry, to which PFE belongs, ranks poorly at 217 out of over 250 industries, representing the bottom 14%. This industry ranking underscores the challenges and competitive landscape within the medical sector.

As PFE prepares to unveil its earnings report, investors are closely monitoring the company’s performance amidst market fluctuations and industry challenges. Analyst insights and valuation metrics provide valuable perspectives for decision-making, highlighting both opportunities and risks associated with Pfizer stock. With the earnings release drawing near, market participants remain attentive to any developments that could influence Pfizer’s trajectory in the coming quarters.

Also Read: Exploring the Pros and Cons of Veneers: A Comprehensive Guide

[bazaarbite]

What are some high return stocks?

Investing in individual stocks can potentially lead to high returns, but it's important to remember that it also comes with higher risk compared to diversified investments like index funds or ETFs. High return stocks often belong to companies with strong growth potential, innovative products or services, solid financials, and a competitive edge in their industry. However, these stocks can be volatile and may experience significant price fluctuations.

Here are some types of stocks that investors often consider for their potential for high returns:

Technology Stocks: Companies in the technology sector can offer high growth potential, especially those involved in areas like cloud computing, artificial intelligence, e-commerce, and software-as-a-service (SaaS). Examples include Apple Inc. (AAPL), Amazon.com Inc. (AMZN), Alphabet Inc. (GOOGL), and Microsoft Corporation (MSFT).

Biotech and Pharmaceutical Stocks: Biotechnology and pharmaceutical companies can see significant stock price movements based on the success of drug trials, FDA approvals, and breakthrough treatments. Examples include Moderna Inc. (MRNA), Pfizer Inc. (PFE), Biogen Inc. (BIIB), and Vertex Pharmaceuticals Incorporated (VRTX).

Consumer Discretionary Stocks: Companies that provide non-essential goods and services may experience strong growth during periods of economic expansion. This sector includes companies in retail, entertainment, travel, and luxury goods. Examples include Tesla Inc. (TSLA), Netflix Inc. (NFLX), Nike Inc. (NKE), and Starbucks Corporation (SBUX).

Renewable Energy Stocks: With increasing awareness of climate change and sustainability, companies involved in renewable energy, such as solar, wind, and electric vehicles, are gaining attention. Examples include Tesla Inc. (TSLA), NextEra Energy Inc. (NEE), Enphase Energy Inc. (ENPH), and Plug Power Inc. (PLUG).

Growth Stocks: These are companies that are expected to grow at an above-average rate compared to other companies in the market. Growth stocks may not always pay dividends but reinvest earnings to fuel further growth. Examples include Zoom Video Communications Inc. (ZM), Square Inc. (SQ), Shopify Inc. (SHOP), and Peloton Interactive Inc. (PTON).

While these stocks have the potential for high returns, it's crucial to conduct thorough research, consider your risk tolerance, and diversify your investments to mitigate risk. Additionally, past performance is not indicative of future results, so it's essential to invest with a long-term perspective. If you're uncertain, consider consulting a financial advisor before making investment decisions.

LTP Calculator Overview:                 

LTP Calculator is a comprehensive stock market trading tool that focuses on providing real-time data, particularly the last traded price of various stocks. Its functionality extends beyond a conventional calculator, offering insights and analytics crucial for traders navigating the complexities of the stock market.

Also Available on Play store  -  Get the App

Key Features:

Real-time Last Traded Price:

The core feature of LTP Calculator is its ability to provide users with the latest information on stock prices. This real-time data empowers traders to make timely decisions based on the most recent market movements.

User-Friendly Interface:

Designed with traders in mind, LTP Calculator boasts a user-friendly interface that simplifies complex market data. This accessibility ensures that both novice and experienced traders can leverage the tool effectively.

Analytical Tools:

Beyond basic price information, LTP Calculator incorporates analytical tools that help users assess market trends, volatility, and potential risks. This multifaceted approach enables traders to develop a comprehensive understanding of the stocks they are dealing with.

Customizable Alerts:

Recognizing the importance of staying informed, LTP Calculator allows users to set customizable alerts for specific stocks. This feature ensures that traders receive timely notifications about significant market movements affecting their portfolio.

Vinay Prakash Tiwari - The Visionary Founder:

At the helm of LTP Calculator is Vinay Prakash Tiwari, a renowned figure in the stock market training arena. With a moniker like "Investment Daddy," Tiwari has earned respect for his expertise and commitment to empowering individuals in the financial domain.

Professional Background:

Vinay Prakash Tiwari brings a wealth of experience to the table, having traversed the intricacies of the stock market for several decades. His journey as a stock market trainer has equipped him with insights into the challenges faced by traders, inspiring him to develop tools like LTP Calculator.

Philosophy and Approach:

Tiwari's approach to stock market training revolves around education, empowerment, and simplifying complexities. LTP Calculator reflects this philosophy, offering a tool that aligns with his vision of making stock market information accessible and understandable for all.

Educational Initiatives:

Apart from his contributions as a tool developer, Vinay Prakash Tiwari has actively engaged in educational initiatives. Through online courses, webinars, and seminars, he has shared his knowledge with aspiring traders, reinforcing his commitment to fostering financial literacy.

In conclusion, LTP Calculator stands as a testament to Vinay Prakash Tiwari's dedication to enhancing the trading experience. As the financial landscape continues to evolve, tools like LTP Calculator and visionaries like Tiwari sir play a pivotal role in shaping a more informed and empowered community of traders.

[tritonmarketresearchamey]

Trending Solutions in the Pharmaceutical Supply Chain Management Market

As the pharmaceutical supply chain continues to evolve and adapt, it faces new challenges and opportunities, prompting the sector to seek innovative solutions for a future of efficiency and reliability. The World Health Organization has reported that approximately 80% of the global population relies on medicines. This sheer dependence underscores the importance of establishing a streamlined and efficient supply chain that reliably delivers medicines. Our estimates indicate that the global pharmaceutical supply chain management market is projected to attain a revenue of $4203.32 million by 2030, rising at a CAGR of 8.70% during the 2023-2030 forecast period.

The escalating demand for pharmaceutical supply chain solutions can be attributed to the factors that underscore the imperative for heightened efficiency and transparency. As per the study, global pharmaceutical expenditure is expected to soar by $1.5 trillion by 2023. Notably, in 2021, China became the world’s second-largest pharmaceutical market, accentuating the urgency for adept supply chain solutions. These adoptions have significantly fueled the demand for SCM, thus driving the Asia-Pacific pharmaceutical supply chain management market to experience the fastest growth in the coming years.

Pharma Supply Chain Disruptions: Potential Tech Solutions

Pharmaceutical executives cite supply chain vulnerabilities as a major factor in their susceptibility to disruption. While these risks are unavoidable, companies can target their impact by increasing visibility, implementing robust risk management strategies, and leveraging advanced technologies.

Most widely embraced pharmaceutical supply chain management solutions:

Transportation Management System

A transportation management system (TMS) is a technology-enabled logistics platform that plays a central role in helping companies efficiently and strategically plan and optimize product movement. Particularly within temperature-sensitive pharmaceuticals, TMS takes on an added dimension by seamlessly integrating temperature monitoring solutions. According to the World Health Organization, improper temperature control can result in up to 35% of vaccines being wasted worldwide yearly.

Moreover, the Drug Supply Chain Security Act (DSCSA) reinforces TMS’s importance. Under the DSCSA, companies must comply with drug transportation regulations to ensure patient safety. Non-compliance can result in penalties of up to $500,000 per violation.

As Triton’s analysis indicates, the pharmaceutical supply chain management market by transportation management system is expected to advance at the fastest CAGR of 8.79% over the projected years 2023-2030.

Warehouse and Inventory Management System

An effective warehouse and inventory management system is essential within the pharmaceutical supply chain, facilitating seamless medicine flow. Maintaining optimal stock levels is a delicate balancing act and a robust warehouse system that orchestrates it flawlessly. Companies like Pfizer have reported a substantial reduction in stock levels, leading to reduced holding costs and improved cash flow.

This system’s benefits surpass financial gains. Minimized wastage is a significant victory for businesses and environmental preservation. According to a study, pharmaceutical waste constitutes 10% of global waste. Efficient inventory management significantly curbs this. In the United States, such implementation saved pharmaceutical firms around $8 billion annually through waste reduction.

Manufacturing Execution System

The global uptake of manufacturing execution systems (MES) is rapidly gaining momentum. This robust adoption is driven by MES’s ability to streamline the entire manufacturing process, fostering seamless operations from raw material input to finished goods production.

A tangible illustration of this efficacy emerges through Johnson & Johnson, a pharmaceutical giant that strategically integrated an MES across its production facilities. This strategic move yielded a 20% reduction in manufacturing cycle time, accelerating the time-to-market for critical medications.

Strategic Collaborations among Key Players

Manhattan Associates Inc: Manhattan Associates is a pharmaceutical supply chain management software company. It partnered with global pharmaceutical firms to enhance the efficiency of their distribution networks.

Oracle Corporation: Oracle is a prominent supplier of cutting-edge technology solutions tailored for the pharmaceutical supply chain management sector. Incorporating NetSuite into Oracle’s offerings bolsters operational transparency and effectiveness, streamlining manufacturing and distribution processes easily. NetSuite, a SaaS application, is a platform for comprehensive business management.

Cardinal Health Inc: In July 2017, Cardinal Health, a company specializing in healthcare products and services, finalized the purchase of Medtronic’s divisions encompassing patient care, deep vein thrombosis, and nutritional insufficiency. It also partnered with Bendcare to develop a comprehensive suite of solutions, aiding rheumatology practices’ financial health and success across the nation.

Conclusion

As the healthcare sector expands globally, streamlined supply chain management ensures the timely and accurate delivery of medicines to patients. Technological advancements are key in reshaping the pharmaceutical supply chain management market. In addition, sustainable practices and innovative solutions are making the sector better equipped than ever to overcome challenges and meet the evolving needs of patients worldwide.

 

FAQs:

Q1) Which key segments are considered in the pharmaceutical supply chain management market?

Component and deployment mode are the segments studied in the given market.

Q2) What major hurdle does the analyzed market encounter?

Technical issues with SCM software are affecting the market’s growth.

[usnewsper-business]

Stock Market Swings Amid Geopolitical Tensions: Tech Stocks Drop, Healthcare Rises #Apple #bullrun #centralbanks #correction #DowJonesIndustrialAverage #earningsgrowth #energystocks #geopoliticaltensions #globaloilsupplies #healthcarestocks #InterestRates #IranianMajorGeneralQasemSoleimani #loftyvaluations #marketdirection #Merck #Microsoft #MiddleEast #NASDAQComposite #oilprices #pfizer #Recession #SP500 #Stockmarket #techstocks #USdronestrike

[tinyshe]

Story at-a-glance

Big Pharma and mainstream media are largely owned by two asset management firms: BlackRock and Vanguard

Drug companies are driving COVID-19 responses — all of which, so far, have endangered rather than optimized public health — and mainstream media have been willing accomplices in spreading their propaganda, a false official narrative that leads the public astray and fosters fear based on lies

Vanguard and BlackRock are the top two owners of Time Warner, Comcast, Disney and News Corp, four of the six media companies that control more than 90% of the U.S. media landscape

BlackRock and Vanguard form a secret monopoly that own just about everything else you can think of too. In all, they have ownership in 1,600 American firms, which in 2015 had combined revenues of $9.1 trillion. When you add in the third-largest global owner, State Street, their combined ownership encompasses nearly 90% of all S&P 500 firms

Vanguard is the largest shareholder of BlackRock. Vanguard itself, on the other hand, has a unique structure that makes its ownership more difficult to discern, but many of the oldest, richest families in the world can be linked to Vanguard funds

What does The New York Times and a majority of other legacy media have in common with Big Pharma? Answer: They’re largely owned by BlackRock and the Vanguard Group, the two largest asset management firms in the world. Moreover, it turns out these two companies form a secret monopoly that own just about everything else you can think of too. As reported in the featured video:1,2

“The stock of the world’s largest corporations are owned by the same institutional investors. They all own each other. This means that ‘competing’ brands, like Coke and Pepsi aren’t really competitors, at all, since their stock is owned by exactly the same investment companies, investment funds, insurance companies, banks and in some cases, governments.

The smaller investors are owned by larger investors. Those are owned by even bigger investors. The visible top of this pyramid shows only two companies whose names we have often seen …They are Vanguard and BlackRock.

The power of these two companies is beyond your imagination. Not only do they own a large part of the stocks of nearly all big companies but also the stocks of the investors in those companies. This gives them a complete monopoly.

A Bloomberg report states that both these companies in the year 2028, together will have investments in the amount of 20 trillion dollars. That means that they will own almost everything.’”

Who Are the Vanguard?

The word “vanguard” means “the foremost position in an army or fleet advancing into battle,” and/or “the leading position in a trend or movement.” Both are fitting descriptions of this global behemoth, owned by globalists pushing for a Great Reset, the core of which is the transfer of wealth and ownership from the hands of the many into the hands of the very few.

Interestingly, Vanguard is the largest shareholder of BlackRock, as of March 2021.3,4 Vanguard itself, on the other hand, has a “unique” corporate structure that makes its ownership more difficult to discern. It’s owned by its various funds, which in turn are owned by the shareholders. Aside from these shareholders, it has no outside investors and is not publicly traded.5 As reported in the featured video:6,7

“The elite who own Vanguard apparently do not like being in the spotlight but of course they cannot hide from who is willing to dig. Reports from Oxfam and Bloomberg say that 1% of the world, together owns more money than the other 99%. Even worse, Oxfam says that 82% of all earned money in 2017 went to this 1%.

In other words, these two investment companies, Vanguard and BlackRock hold a monopoly in all industries in the world and they, in turn are owned by the richest families in the world, some of whom are royalty and who have been very rich since before the Industrial Revolution.”

While it would take time to sift through all of Vanguard’s funds to identify individual shareholders, and therefore owners of Vanguard, a quick look-see suggests Rothschild Investment Corp.8 and the Edmond De Rothschild Holding are two such stakeholders.9 Keep the name Rothschild in your mind as you read on, as it will feature again later.

The video above also identifies the Italian Orsini family, the American Bush family, the British Royal family, the du Pont family, the Morgans, Vanderbilts and Rockefellers, as Vanguard owners.

BlackRock/Vanguard Own Big Pharma

According to Simply Wall Street, in February 2020, BlackRock and Vanguard were the two largest shareholders of GlaxoSmithKline, at 7% and 3.5% of shares respectively.10 At Pfizer, the ownership is reversed, with Vanguard being the top investor and BlackRock the second-largest stockholder.11

Keep in mind that stock ownership ratios can change at any time, since companies buy and sell on a regular basis, so don’t get hung up on percentages. The bottom line is that BlackRock and Vanguard, individually and combined, own enough shares at any given time that we can say they easily control both Big Pharma and the centralized legacy media — and then some.

Why does this matter? It matters because drug companies are driving COVID-19 responses — all of which, so far, have endangered rather than optimized public health — and mainstream media have been willing accomplices in spreading their propaganda, a false official narrative that has, and still is, leading the public astray and fosters fear based on lies.

To have any chance of righting this situation, we must understand who the central players are, where the harmful dictates are coming from, and why these false narratives are being created in the first place.

As noted in Global Justice Now’s December 2020 report12 “The Horrible History of Big Pharma,” we simply cannot allow drug companies — “which have a long track record of prioritizing corporate profit over people’s health” — to continue to dictate COVID-19 responses.

In it, they review the shameful history of the top seven drug companies in the world that are now developing and manufacturing drugs and gene-based “vaccines” against COVID-19, while mainstream media have helped suppress information about readily available older drugs that have been shown to have a high degree of efficacy against the infection.

BlackRock/Vanguard Own the Media

When it comes to The New York Times, as of May 2021, BlackRock is the second-largest stockholder at 7.43% of total shares, just after The Vanguard Group, which owns the largest portion (8.11%).13,14

In addition to The New York Times, Vanguard and BlackRock are also the top two owners of Time Warner, Comcast, Disney and News Corp, four of the six media companies that control more than 90% of the U.S. media landscape.15,16

Needless to say, if you have control of this many news outlets, you can control entire nations by way of carefully orchestrated and organized centralized propaganda disguised as journalism.

If your head is spinning already, you’re not alone. It’s difficult to describe circular and tightly interwoven relationships in a linear fashion. The world of corporate ownership is labyrinthine, where everyone seems to own everyone, to some degree.

However, the key take-home message is that two companies stand out head and neck above all others, and that’s BlackRock and Vanguard. Together, they form a hidden monopoly on global asset holdings, and through their influence over our centralized media, they have the power to manipulate and control a great deal of the world’s economy and events, and how the world views it all.

Considering BlackRock in 2018 announced that it has “social expectations” from the companies it invests in,17 its potential role as a central hub in the Great Reset and the “build back better” plan cannot be overlooked.

Add to this information showing it “undermines competition through owning shares in competing companies” and “blurs boundaries between private capital and government affairs by working closely with regulators,” and one would be hard-pressed to not see how BlackRock/Vanguard and their globalist owners might be able to facilitate the Great Reset and the so-called “green” revolution, both of which are part of the same wealth-theft scheme.

That assertion will become even clearer once you realize that this duo’s influence is not limited to Big Pharma and the media. Importantly, BlackRock also works closely with central banks around the world, including the U.S. Federal Reserve, which is a private entity, not a federal one.18,19 It lends money to the central bank, acts as an adviser to it, and develops the central bank’s software.20 

  “In all, BlackRock and Vanguard have ownership in some 1,600 American firms, which in 2015 had combined revenues of $9.1 trillion. When you add in the third-largest global owner, State Street, their combined ownership encompasses nearly 90% of all S&P 500 firms. “

BlackRock/Vanguard also own shares of long list of other companies, including Microsoft, Apple, Amazon, Facebook and Alphabet Inc.21 As illustrated in the graphic of BlackRock and Vanguard’s ownership network below,22 featured in the 2017 article “These Three Firms Own Corporate America” in The Conversation, it would be near-impossible to list them all.

In all, BlackRock and Vanguard have ownership in some 1,600 American firms, which in 2015 had combined revenues of $9.1 trillion. When you add in the third-largest global owner, State Street, their combined ownership encompasses nearly 90% of all S&P 500 firms.23

A Global Monopoly Few Know Anything About

To tease out the overarching influence of BlackRock and Vanguard in the global marketplace, be sure to watch the 45-minute-long video featured at the top of this article. It provides a wide-view summary of the hidden monopoly network of Vanguard- and BlackRock-owned corporations, and their role in the Great Reset. A second much shorter video (above) offers an additional review of this information.

How can we tie BlackRock/Vanguard — and the globalist families that own them — to the Great Reset? Barring a public confession, we have to look at the relationships between these behemoth globalist-owned corporations and consider the influence they can wield through those relationships. As noted by Lew Rockwell:24

“When Lynn Forester de Rothschild wants the United States to be a one-party country (like China) and doesn’t want voter ID laws passed in the U.S., so that more election fraud can be perpetrated to achieve that end, what does she do?

She holds a conference call with the world’s top 100 CEOs and tells them to publicly decry as ‘Jim Crow’ Georgia’s passing of an anti-corruption law and she orders her dutiful CEOs to boycott the State of Georgia, like we saw with Coca-Cola and Major League Baseball and even Hollywood star, Will Smith.

In this conference call, we see shades of the Great Reset, Agenda 2030, the New World Order. The UN wants to make sure, as does [World Economic Forum founder and executive chairman Klaus] Schwab that in 2030, poverty, hunger, pollution and disease no longer plague the Earth.

To achieve this, the UN wants taxes from Western countries to be split by the mega corporations of the elite to create a brand-new society. For this project, the UN says we need a world government — namely the UN, itself.”

As I’ve reviewed in many previous articles, it seems quite clear that the COVID-19 pandemic was orchestrated to bring about this New World Order — the Great Reset — and the 45-minute video featured at top of article does a good job of explaining how this was done. And at the heart of it all, the “heart” toward which all global wealth streams flow, we find BlackRock and Vanguard.

- Sources and References

[jennymanrique]

Contra-Vax

Vaccines to the rescue? Only if people roll up their sleeves. Photo courtesy of Valleywise Health

Science moved at unprecedented speed to develop vaccines against the new coronavirus. It was too fast for some latinos -- especially those egged on by myth and misinformation 

On the ranch where Gabriela Navarrete was raised in the northern Mexican state of Chihuahua, she learned early on that the land could provide what she needed to cure her ills. Mesquite bark, olive oil, corn vinegar and baking soda were useful for treating everything from joint pains to throat infections. In case of indigestion, the medicine was a good old stomach rub.

Navarrete, 69, passed on to her three daughters and one son the lesson that "everything natural is what is good for the body."

So when the COVID-19 pandemic began, she quickly stocked up on Vitamin C, infusions of ginger, chamomile and peppermint, and linden tea for sleeping.

And while this arsenal failed to defend her against the coronavirus last year, she remains resolute: Her principle of "consuming everything natural," she said, is more powerful than the idea of getting vaccinated.

That's why she’s decided that the new COVID vaccines are not for her.

"Getting the vaccine is going to be very bad for me because I think they are made from the virus itself," Navarrete said, talking from her home in Anthony, New Mexico, a small town on the border with Texas. "The only time I got the flu shot, I got a lot worse and I don't want to do that to my body anymore."

Graciela Navarrete and her grandson, Diego.

The coronavirus reached Navarrete’s family through her 17-year-old daughter, an athlete who resumed volleyball practice once the school gym was opened after the lockdown. Everyone avoided hospitalization. They were treated by the family doctor with antibiotics, ibuprofen and albuterol in inhalers.

"The virus gave me very bad headaches and I still struggle when walking, so I accepted the medicines. But I am definitely not getting vaccinated."

Like others her age, Navarette is at a higher risk of infection. Yet that’s not enough for her or her children to discount messages they’ve gotten via WhatsApp, complete with videos, that claim, for example, that vaccines are made with tissues of aborted fetuses.

Doubts and fears 

Nationwide, people across demographic lines have lingering doubts about the new COVID-19 vaccines, according to a new survey by the Monmouth University Polling Institute.

Half of the survey respondents said they plan to get vaccinated as soon as they’re allowed to. But 19% say they want to first see how others react to the inoculations, while 24% say they will avoid the vaccine if they can.

Among Latinos, according to recent data from the COVID-19 vaccine monitor launched by the Kaiser Family Foundation (KFF) to track attitudes and experiences with the vaccines, 18% of adults said they will definitely not get the vaccine. Another 11% said they will only do so if it’s required by employers. And, among those who have decided that they will get vaccinated, 43% said they want to wait and see how the innoculations affect other Latinos.

According to the United States Centers for Disease Control and Prevention, Latinos are nearly twice as likely to be infected by COVID-19 as non-Latino whites. The same population is more than four times as likely to be hospitalized and almost three times as likely to die of the virus. This is due, partly, to the large number of Latinos working in essential jobs that expose them to co-workers and the public. Other factors, like access to health care, also play a role.

Despite the higher risk, some Latinos remain uncertain about the safety of the new coronavirus vaccines.

An example: Navarrete in Texas, said she believes the myth that vaccines carry bits of an actual virus.

"There are other vaccines that have virus particles, including live virus particles," said Gerardo Capo, chief of hematology at Trinitas Comprehensive Cancer Center in New Jersey. "This vaccine is more modern. It has internal proteins of the virus that are not considered to cause an infection. It is impossible."

Vaccine hesitancy among Latinos in the U.S. is not necessarily an ideological issue or a belief in the anti-vaccine movement. "It has more to do with not having enough information or having inadequate information," said Nelly Salgado de Snyder, a researcher with  the University of Texas at Austin.

Doubts exist even among Latino health care professionals.

Ada Linares, a nurse in the New York area, told palabra. that it’s not the suspicious messaging seen on social media or via WhatsApp texts, but her own unfamiliarity with this vaccine -- how it was developed and potential side effects perhaps overlooked in testing and trials that moved at unprecedented speed.

“I have always been pro-vaccine, and I think this is why we are here today,” she said. “But at the same time, I don’t know much about (the vaccines).”

Nurse Ada Linares hesitated for some time but she eventually rolled up her scrubs and took her doses. Photo: Jorge Melchor

Avoiding the needle 

In Texas, officials started by vaccinating health care workers, residents of nursing homes and some people older than 65 years.

Throughout the state, according to the KFF monitor, only 15% of vaccines have reached Hispanics, even though Latinos account for almost 40% of the population, 44% of coronavirus cases and almost half of COVID-19 deaths.

"We need to focus on equity as part of the COVID-19 vaccination effort," said Samantha Artiga, director of KFF's racial equity and health policy program. "It is important to monitor data by race and ethnicity to understand the experiences of the communities ... , who is receiving the vaccines, and who has been the most affected by the pandemic."

But it’s more than just reluctance. Studies into low flu vaccination rates among low-income Latino seniors show that being uninsured -- and even the lack of transportation to get to vaccination centers -- are huge barriers.  

Experts suggest that no-cost COVID-19 vaccines, available to everyone regardless of health insurance or immigration status, could help close the gap, “if the information is available in linguistically appropriate materials and the concerns of people are clearly addressed. Immigrant families should be assured that their medical data is private and will not be used by federal agencies,” Artiga said.

Conspiracy theories

In addition to debunked conspiracy theories that Pfizer and Moderna vaccines can alter DNA, or contain microchips implanted by Bill Gates to monitor people with 5G technology, other rumors specific to the Latino community have spread through social media.

“The viral disinformation includes anonymous voice messages on WhatsApp that say that since Trump does not like Mexicans and built the wall, he wants to vaccinate us so we cannot have more children, or that the vaccine is a poison for those of us who are here undocumented, that it is a way to get rid of us,” Salgado de Snyder said.

Photo illustration by FrankHH/Shutterstock

She suggested one possible reason such disinformation is embraced: “People believe it because they don't have the level of education or the institutional support to confirm this information that they hear from other Latinos. Many of them do not speak English and most of the scientific information is not available in Spanish,” she said.

Salgado de Snyder is the co-author of the study, “Exploring Why Adult Mexican Males Do Not Get Vaccinated: Implications for COVID-19 Preventive Actions,” conducted by the Migrant Clinicians Network and published last September.

Data was collected in 2019 at the Ventanilla de Salud at the Mexican Consulate in Austin. Before the pandemic, the clinic offered free vaccines against maladies like influenza, tetanus, hepatitis A and B, and human papilloma, in association with Austin Public Health.

Some 400 patients gave researchers a variety of reasons for not getting vaccinated, including lack of time or money, fear of injections and of potential side effects, insufficient information or motivation, and the perception that they are  healthy and don’t need inoculation.

"While women are more familiar with the health system because in Mexico there is a universal voluntary and free vaccination program, men have the mistaken belief that vaccines are the cure for a problem, they do not see (a vaccination) as a preventive tool," Salgado de Snyder said.

“As breadwinners, they do not want to miss a day of work to go to get vaccinated,” she added. “That is why our recommendations in times of COVID are that through some type of mobile clinic, employers offer vaccines in workplaces such as construction companies or meatpacking plants,” she said.

Moving too fast

María del Rosario Cadena remembers that during her childhood in Tampico, in Mexico’s Tamaulipas state, she received vaccines against hepatitis and polio without any side effects. But she is "very suspicious" about the COVID-19 vaccines that seem to have been developed and approved so quickly.

"I've seen on TV that it affects various parts of the body and people get very sick after receiving it," del Rosario Cadena said.

Maria del Rosario Cadena

Apart from her doubts about the vaccine, del Rosario Cadena insists she follows all recommendations to guard against COVID-19: She wears a mask, she practices social distancing, and she’s always washing her hands. And, since she doesn’t go out "at all," the 71-year-old said she believes that “isolation is my vaccine. I feel I don't need it."

Her daughter, Rocio Valderrabano, 55, is diabetic, so she will soon have access to a COVID-19 vaccine. But she has doubts, so she’ll wait and see how some friends -- nurses -- react to their second doses. "I know people who have had COVID and spent four days with oxygen. I know they had a very bad time ... but I still want to wait and see if there are side effects (to the vaccine)."

Clinicians said mistrust also comes from knowing there were few people of color in the vaccine trials. In the trial for the Pfizer-BioNTech vaccine, participants were 13% Latino, 10% African American, 6% Asian, and 1% Native American. Moderna’s trial population was 20% Hispanic, 10% African American, 4% Asian.

"We hope that the labs that are developing new vaccines will include more Latino patients in their trials," said Dr. Lucianne Marin, a pediatrician at Los Barrios Unidos Community Clinic in Dallas, one of 75 community centers in Texas that will provide vaccines in immigrant neighborhoods.

Marin and the rest of the Barrios Unidos staff have already received both doses --  injections that caused her "a bit of discomfort, fatigue, and a headache."

“Anything strange that enters the body can cause a reaction,” she said. “But one has to understand that the vaccine is not made from the live virus. It’s from genetic material that will help to generate antibodies. … I tell my patients that a fever or a pain in the body cannot be compared with the exposure to the coronavirus.”

The community clinics are out to debunk myths and dispel fears. They emphasize the greater risk of infection for Latinos who have chronic health problems like diabetes, hypertension, and excessive weight.

In doctor’s offices or in telemedicine visits they invite grandmothers to be champions in their families and spread the message about the need to get vaccinated. “Among Latinos, the elders of the family are highly respected and they are listened to; if they are convinced (of the vaccine), the family will be too,” Marin said.

Community health workers also share messages on Facebook, or partner with local Spanish-language media on virtual discussions featuring doctors and public officials -- even representatives from consulates of Latin American countries.

“It is our job to be the reliable messenger,” Marin said. “Vaccines are safe and free.”

Originally published here

Want to read this piece in Spanish? Click here

[danielude-blog]

Daniel Eduardo Serrato Ude

Public Accountant - Financial Services / Current student of Master in Management

Current student of Master in Management in France - ESC Clermont- Ferrand. Bachelor Degree of Accounting at Externado University. Solid experience in analizing financial and accounting information from different companies, as well as in transaction services (due diligence) giving support for different sectors - Industrial, services and banking. In addition, professional background in consolidation and reporting, and daily accounting processes with SAP. Furthermore, I am fluent in 4 languages (Spanish, English, French and Portuguese) and intermediate level of speaking in Russian. Skills to adapt to change, fast learning and teamwork under pressure. Autonomous, responsible and motivated by constant learning and growth both professionally and personally.

PROFESSIONEL EXPERIENCES

 KPMG S.A.S.    //    Staff (Transaction services - due diligence)

                               Colombia/ November 2017 – August 2018 (9 months)

 * Understanding, analysis and synthesis of financial information and information of interest of different companies for decision making.

* Calculation and analysis of reported and adjusted EBITDA, net debt and working capital.

* Summary of recommendations and important results for the development of the transaction and decision making.

* Contact the customer and the target to get information.

 Aspen Labs    //   Accounting analyst

                   Colombia / February 2015 – December 2016 (1 year 10 months)

* Realization of reports of revenue and costs for the headquarter.

* Assist in the reporting of financial information to the headquarter.

* Validation and control of employee´s expenses.

* Make accounting assignments and reconciliations of accounts.

* Check and analyse balances and movements in accounts in balance sheets and income statements of the company.

* Preparation and validation of information for audits and tax outsourcing.

Succeeded in:

1. Establishment and staff training of a new expenditure legalization tool,

2. Creating new transactions in SAP with the corresponding support for a more efficient information flow.

Pfizer S.A.S.    //   Accounting analyst (Internship)

                            Colombia/ January 2013- July 2013 (7 months)

* Review and control the company's fixed assets.

* Make accounting assignments and reconciliations of accounts.

* Check balance sheet accounts and administrative expenses.

EDUCATION

2018 - 2020 Groupe ESC Clermont

Master in Management

2010 - 2015 University Externado of Colombia

Studies in public accounting applied to business management

Personal skills

Languages:

Spanish - Mother tongue

English - Fluent

French – Fluent

Portuguese - Intermediate

Russian - Spoken

Related to finance:

- Preparation and analysis of financial and accounting information.

- SAP (FI)

- Analysis of EBITDA, working capital and net debt.

- Asset management.

Others:

- Adaptation to change

- Customer service

- Team work

- Fast learner

- Advanced use of Microsoft tools.

Progress of axes in the Master degree

Status of goals related to my Master degree

First Master´s Internship - Gap year

                                    Valeo

Daily indicators of revenue, stock, wasted inventory .

Weekly best estimated of sales

Monthly Reporting groupe (Actual – budget – forecast) in SAP Financial Consolitation

Weekly reporting of direct labor efficiency of production

Validation for the monthly closing of sales, transport, inventory, NQC, selling expenses, along other.

Daily validation of transport invoices, purchase requisitions, inventory differences and IDOCs in SAP

Professional plan

I want to continue with the path in due diligence that I had before starting my Master.

Consultant transactions services

A transaction services consultant participates in the development of accounting and financial due diligence procedures, in connection with acquisition and sales transactions on behalf of Corporate and / or Private Equity clients.

 Required Skills

1.      Technical skills

Advanced accounting concepts including new standards

Computer tools (spreadsheets, databases)

In-depth economic and financial culture

Writing high capacity (clear and factual summaries)

English (working language)

2.      Professional Skills

Availability and responsiveness (respect of deadlines and emergencies)

High stress resistance (maximum availability required, highly exposed position for experienced consultants)

Political sense, ability to negotiate

Relational and multidisciplinary team work (firmness and diplomacy)

Sense of organization (manage different internal or external consulting teams, in sensitive contexts)

Ability to anticipate: detect any new opportunity that can turn into a merger-acquisition operation.

                                                       Linkedin

https://www.linkedin.com/in/daniel-serrato-ude-649978b9/

                                                       Thank you

[sycriptouk]

Deep Biontech (BNTX) analysis and why i think a rally could start after Q3 earnings tomorrow

Forecast for this week (see full details on financials further down)

This week BNTX will shine; Q3 ER on Tuesday and oncology congress 10-14 November (see pipeline below). Moderna missed earning last week and reduced the guidance for 2021; this reduction was not driven by lack of demand, it was driven by delays in manufacturing. BNTX-PFE jumped in and took over the demand Moderna failed to serve. The current drop is still an overreaction of the market to the Pfizer anti-viral which cause a lot of Stop/Loss drops and liquidation of call options.

Pfizer has recently announced Q3 revenue from Comirnaty to be $13 Bn, and raised the 2021 FY forecast from $33 Bn to $36 Bn. Consensus estimate is $12.27 EPS Q3. We estimate a somewhat better result, $12.75 at minimum, driven by a/o higher sales volume and improved financing result. Similar to what happened to this stock for Q4 2020 earning on March 31st 2021, the most likely scenario is a rally starting directly after the Q3 earnings.

​

Market manipulation

Biontech is a fairly new stock on the Nasdaq and due to its small freefloat of approx. 240m shares, it got highly manipulated by market makers the recent year.

It seems like big money and algos are trading Biontech and Moderna as only one mRNA-Stock. Both stocks are glued together, although they should have a contrary movement. (i.g. Biontech gets its FDA approval, Moderna goes up; Pfizer reporting a surpass of the quarterly estimates, Moderna goes up). Neglecting some more money flow to Moderna, their movement is sync by seconds on a daily basis.

​

Biontech vs Moderna

Biontech vs Moderna

Market share

Plain and simple Comirnaty is dominating the vaccine race in western world and now rapidly expanding to takeover Sputnik and the Chinese vaccines in Latam and other regions that relied on those vaccines at the start of the pandemic

​

https://preview.redd.it/yq3r2q1cvdy71.png?width=478&format=png&auto=webp&s=d08eb6888077a96c5e8817a944a41a5e6ea7be6d

​

https://preview.redd.it/34dszcucvdy71.png?width=624&format=png&auto=webp&s=5d4c5244f5180ffe235a7b0fa7b347fe081bf70d

​

Proof of concept

Biontech was the first company in the world with a real vaccine for corona. Uğur Şahin was standing beside Donald Trump in front of the White House while announcing this news.

Other companies tried to follow suit, but the most of them failed (i.e. Curevac). Only Moderna could produce another working mRNA vaccine.

This proof of concept can be extrapolated to all other vaccines in their pipeline and Biontech has the highest likelihood for a good outcome.

• Safety

Comparing all vaccines available on the market, Comirnaty has the lowest side effects of all.

AstraZeneca had a lot of issues and is no longer used in the European Union, never got authorized in the US. Moderna has also a higher risk of heart inflammations and it’s use got stopped in countries like Finland, Sweden, Norway, Denmark, Iceland for males under 30 years old. The FDA recently authorized under EUA the use of Comirnaty for children over 5 years old. In contrast, Moderna’s authorization for children above 12 got delayed to at least January. The Biden administration has purchased enough pediatric doses to vaccinate 100% of children between 5 and 11 years old. This gives Biontech a monopoly for children vaccination.

• Capacity

The demand for COVID vaccines is huge and the biggest bottleneck has been and continues to be production capacity and where vaccine manufacturers have struggled. This is where Biontech in partnership with Pfizer have done a stellar job ramping up manufacturing capacity from original 2021 estimate of 1Bn to 3Bn doses for 2021, followed by 4bn doses in 2022 and beyond. To reach this goal they have already a new production building in Marburg Germany with a capacity of 1bn doses a year.

Biontech is also expanding their production all over the world. In 2022, they will start a production building in Singapur and also in Africa with a cooperation with Ruanda and Senegal, in cooperation with the national governments and co-funded by international donors. In addition they have entered in a joint venture with the Chinese company Fosun, plans for and are building another plant with a capacity of 1 bn doses for the Chinese Asian market have been announced.

• COVID outlook, from pandemic to endemic

No matter which vaccine you’ll take, the protection efficacy is waning. The coronavirus is also mutating constantly to new variants, just like the flu. You don’t need an accurate forecast to realize that the virus is here to stay. All over the world, the governments are starting the 3rd booster jab. Talks about a 4th booster are already taking place. An annual vaccination will be the rule, once again think about the flu, exact same but for a much more deadly and infectious virus. We’ll see a constant cashflow. While most analysts are just too afraid to announce this in public still ignore this, BoFA has been estimating an annual booster demand at the size of flu vaccination demand, 58% of population in industrialised countries. The EU has secured 450m booster doses for each of 2022 and 2023, with an option for doubling should two booster shots per year become necessary. Booster prices have been raised by some 25% or more in most industrialized countries, including EU, USA, and the UK over 2021 prices, with Pfizer seeing further room for increase when comparing with other vaccines, e.g. against Shingles or Streptococces.

• Cancer pipeline

Biontech has a long-lasting experience in cancer research. They are the technical pinnacle with the mRNA cancer treatment currently and way ahead of all other companies in the world. They have four cancer studies in their 2nd phase which are extremely promising. For instance, they cured cancer of 17 mice out of 20 completely. The other 3 mice shrunk their tumors dramatically. A real cure for cancer is ahead of us! There is an upcoming (11/10-11/14) oncology conference called SITC where Biontech has 7 abstract and a late-breaking presentation. The pipeline includes two PD-L1 antibody combination therapies, developed in cooperation with Genmab, which initial reports call "very promising". The PD-(L)1 antibody market was some 27 bn USD in 2020, with expected annual growth rates of up to 35%, and includes blockbusters such as Keytruda (Merck). Another presentation will be on BioNTech's novel CAR-T-Cell approach using mRNA, which addresses a potential 10 bn USD market by 2024.

· Social responsibility

Biontech and Pfizer are donating 1Bn doses at cost to the US government to be donated free of charge to the 90 poorest countries. They have pledged they will donate additional 1Bn doses to the poorest countries.

• Pipeline

Besides Corona and cancer, they are also working on various vaccines. Their flu vaccine developed for Pfizer has entered Phase 1 clinical trial in September. If successful, BioNTech shall be entitled to some 10% royalty on revenue, plus singificant sales-based milestone payments. Other vaccines under development include for Flu, Malaria, HIV, Tuberculosis, as well as a number yet undisclosed diseases.

• Financials

Pfizer and BioNTech split Comirnaty gross margins 50/50 worldwide except for China (incl. Taiwan), where BioNTech works in a similar arrangement w. Fosun.

Q3 : Pfizer has recently announced Q3 revenue from Comirnaty to be 13 bn USD, and raised the 2021 FY forecast from 33 bn USD to 36 bn. However, the Pfizer business quarters/ years outside the US are December to November, with a June to August Q3. As such, non US-revenues for September 21 are still missing from their Q3 figures, the same applies to Dec. 21 in their annual guidance. Based on a tally of individual contracts that have been reported publicly, Q3 Comirnaty revenue for calendar Q3 is estimated at some $14.15 bn USD (including $190 m via Fosun), and for 2021 at around $45.6 bn (including $615m via Fosun).

Q4: There are still a handful question marks, including the COVAX absorption of US donations. There are more than 100m doses that the US has announced to make available to COVAX in Q4 2021, but which COVAX has so far not allocated and/or assigned a delivery date to. Secondly, there is uncertainty whether monthly delivery of 37.5m booster/Kid vaccine doses to the EU will start in December 21 (Pfizer statement during Q2 ER), or Jan. 22 (EU announcement this summer). Q4 revenue in question is some 850m USD, depending also on the USD/EUR exchange rate.

Annual 2021: The $45.6 bn 2021 revenue forecast represents the optimistic scenario. OTOH, contracts with a number of high-income countries, most notably the Gulf States, Israel and Singapore, have hardly been published. Israel has certainly purchased further boosters and kid vaccines for delivery already in 2021, and the same may be assumed for Saudi Arabia, which has already authorized Comirnaty boosters, and shots for 5-11yos, and are preparing for kid vaccination to still start in 2021. Especially Saudi-Arabia, with a population of 34 million, and exclusively relying on Comirnaty boosters and kid vaccines, could be sizeable in this respect. All in all, there might be an upside potential of some good $500M additional revenue 2021 from yet unpublished / unrecorded booster & kids vaccines contracts. Furthermore, should there be delivery delays to COVAX, it may be assumed that some of the supply will be assigned to Taiwan, possibly bringing in another $210M in revenue in December 21 from there, which is currently assumed to only occur in Q1/22.

Annual 2022: PFE has pre-announced at minimum sales of 1.7 bn doses Comirnaty, for a total revenue of $29 Bn. Note that this forecast only includes contracts signed by Oct. 15, 2021. I.e., recent contracts announced afterwards as e.g. the US purchasing an additional 50m doses of kids vaccines for 2022, S. Korea buying 30m more doses, the Uruguayan purchase of 3.7m doses, and the 3.5m doses to Costa Rica, shall come on top, as shall be major booster contracts still under negotiation such as 150m doses for Brazil, 55m doses for the Phillipines, 50m doses for Vietnam, and a undisclosed quantity for Malaysia. Moreover, the Pfizer forecast will in all likelihood again relate to the "Pfizer Year" outside the US, i.e. 12/21 - 11/22. Importantly, the Pfizer 2022 outlook yields an average price per dose of 17.1 USD. When deducting 800m doses to be supplied as US donation to COVAX at 7 USD/dose, the price on the remainder goes up to even 31.6 USD/dose. This is far higher than the announced booster prices for the US ($24) and the EU ($23), suggesting that most of the other booster contracts already signed, including with Japan, Australia, S. Korea and the UK, should be at prices of 30 USD/dose or above. It also serves as further strong indication of already signed sizeable, and highly priced contracts with several Gulf States, Israel and Singapore."

If a rally starts or not, in the worst case you support a company that saved the world and is working towards curing cancer.

This is not a not financial advise!

​

Position

​

submitted by /u/Muffy_SuperGosu [link] [comments]

from wallstreetbets https://www.reddit.com/r/wallstreetbets/comments/qpf3dx/deep_biontech_bntx_analysis_and_why_i_think_a/ via IFTTT

[itswallstreetpr]

The Vaccine Revolution Portfolio (MRNA, PFE, JNJ, NVAX, BNTX, AZN, DYAI)

As new variants begin to pop up for the plague of the 21st century, one can’t help but wonder if there are unturned stones from an investor standpoint. To back that up, we present the case of Israel – once thought to be the poster child of the perfect path around virus mitigation and vaccination rates for COVID-19, Israel is now emerging as a new hot-spot and cautionary tale. The country that was once predicted to be the first to vaccinate its entire population had the highest per-capita caseload of anywhere in the week through Sept. 4, according to figures compiled by Johns Hopkins University. That’s shocking, but it should be educational as we navigate this process collectively. The moral of the story isn’t that vaccines don’t work – they do. Instead, the moral may be that we are gradually evolving our global strategy for living with a new endemic enemy in the human microbiome, and it will likely involve multiple vaccine iterations over coming years, and the emergence of a new solution that is easy to store, easy and cheap to transport, cheap to produce in scalable quantities ready-made for billions of people multiple times over multiple years, and uncontroversial in its physiological and cellular aspects.  After all, the biology of the situation is no more important than the sociology and anthropology we face. It seems increasingly likely that it will have to be done again and again all around the world. If it can be done simpler, cheaper, faster, and in a manner most people are already more comfortable with, then it clearly has a higher chance of success. With that in mind, we take a look at some recent catalysts among the most important stocks in the vaccine space.   Johnson & Johnson (NYSE:JNJ) became a leadership play in the non-mRNA Covid-19 race late last year and still is likely the most important frontline alternative to the mRNA (Moderna and Pfizer) vaccines on the playing board as of this summer. The company engages in the research and development, manufacture, and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. Johnson & Johnson (NYSE:JNJ) recently announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine. According to the company’s release, in July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization. "We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. "We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination." It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. JNJ shares have been relatively flat over the past month of action, with very little net movement during that period.  Johnson & Johnson (NYSE:JNJ) managed to rope in revenues totaling $23.3B in overall sales during the company's most recently reported quarterly financial data -- a figure that represents a rate of top line growth of 27.1%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($25.3B against $38.7B, respectively).   Dyadic International, Inc. (NASDAQ:DYAI) is one of the most interesting dark-horse plays emerging here. The company recently signed a landmark deal with Sorrento Therapeutics, Inc. (NASDAQ:SRNE), a major player in the biotech space on the vaccine side, as part of a plan to boost its unique vaccine solution to market. The company has a special edge with its fungal-based C1 technology platform, which uses a different vector for producing more vaccine volume faster and cheaper, and its vaccine solution (now starting human testing) is easier to store, produce, transport, and distribute, and cheaper to manufacture quickly, than the mRNA solutions. Dyadic International, Inc. (NASDAQ:DYAI) recently announced, along with SRNE, the signing of a binding term sheet to enter into an exclusive license agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic’s lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadic's proprietary and patented C1-cell protein production platform. The final terms of the license will be set forth in a definitive agreement to be entered into between the parties. Sorrento Chairman and CEO, Dr. Henry Ji, commented, “We look forward to continuing our collaboration with Dyadic, which began last year, initially with a goal of developing and commercializing a protein-based COVID-19 vaccine that can be rapidly manufactured in large quantities in our existing cGMP facilities, and stored and transported at room temperature, in order to increase access and affordability to underserved populations globally.” Dr Ji. continued, “Over the past six months we have carried out several promising preclinical animal studies using the C1-produced RBD antigen in Dyadic’s lead COVID-19 vaccine candidate, DYAI-100. Our goal is to manufacture a COVID-19 vaccine that will provide protection across the variants of concern, including Delta, and in addition, apply the C1 protein production platform broadly across our current and future coronavirus programs.” Mark Emalfarb, Dyadic’s President and Chief Executive Officer noted, “We are delighted to have executed a binding term sheet with Sorrento Therapeutics to license the C1 technology for the development and commercialization of coronavirus vaccines, therapeutics, and diagnostics, including COVID-19. This marks a significant milestone in our corporate development efforts as we expect the license agreement we will enter into to enable us to monetize our internal COVID-19 development efforts with a partner that has the resources and expertise to advance vaccines, therapeutics, and diagnostics both clinically and commercially.” Dyadic International, Inc. (NASDAQ:DYAI) generated research and development revenue of $937k in the quarter ended June 30, 2021 versus $524,000 in the second quarter of 2020, up 79% year over year. Cash and equivalents balance as of June 30, totaled $25.6 million. DYAI could be the most underappreciated name in the space at this point, for multiple reasons.   Novavax, Inc. (NASDAQ:NVAX) is another potential winner when it comes to alternatives to the new mRNA vaccine solutions. The company’s core COVID-19 solution is said to be a step up in terms of manageability for a global population, and it is tracking well on the regulatory front. But the stock has already advanced massively on this narrative and more good news might be an exit door for early players. According to its materials, the company focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome.  Novavax, Inc. (NASDAQ:NVAX) recently announced that the U.S. Centers for Disease Control and Prevention (CDC) has provided updated guidance for those who have been vaccinated as part of a clinical trial in the U.S. The CDC guidance states that participants in the Novavax PREVENT-19 Phase 3 clinical trial meet the criteria to be considered fully vaccinated two weeks after they have completed the vaccine series. "Novavax commends the CDC for its continued support for COVID-19 clinical trial volunteers, with this update providing clarity and guidance for participants in our PREVENT-19 Phase 3 clinical trial," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "We are grateful to all of our clinical trial participants who have helped create a safer future for all." The context for this announcement is a bit of a bid, with shares acting well over the past five days, up about 16% in that timeframe. Shares of the stock have powered higher over the past month, rallying roughly 27% in that time on strong overall action.  Novavax, Inc. (NASDAQ:NVAX) managed to rope in revenues totaling $298M in overall sales during the company's most recently reported quarterly financial data -- a figure that represents a rate of top line growth of 738.6%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels exceeding current liabilities ($2.1B against $1.7B).   Other key players in the space include Moderna Inc (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), BioNTech SE - ADR (NASDAQ:BNTX), and AstraZeneca plc (NASDAQ:AZN). Read the full article

[massivevoidpainter]

buy Ativan lorazepam 2mg online

buy Ativan lorazepam 2mg online buy Ativan lorazepam 2mg online Fresh Stock: 1/28/2018 Product: Ativan Strength: 2mg Active Ingredient: Lorazepam Quality: Up to the mark Brand: Pfizer Blister: $10 extra for every 30 count Discounted prices for bulk orders buy-ativan-lorazepam-2mg-online/ Contact US now for a good deal using any of the info below: Email: zerolakechem@gmsil.com Wickr Id: zerolakechem2021 Whatsapp: +(509) 255-8233 Buy Ativan Online Without Prescription Ativan is a sedative medicine made out of the dynamic substance Lorazepam qualified as the benzodiazepine. It is taking in the treatment of anti-epileptic and mental unsettling influence cure. It works in subcortex of a mind, its piece where feelings are produced and that runs vegetative and emotional procedures. It influences amygdaloidal body consequently stifling tension, calms through the brainstem and thalamic core and discharges writhing by means of the hippocampus. That’s why it is applied to the patient in different kinds of disorder i.e. mental failures, sleep deprivation, convulsive appropriations, psychomotor fomentation, even to plan patients for surgery and to ease alcohol asceticism, and so on buy online at our sites is a simple procedure, you need to know about the given information. The most effective method to buy ativan 2mg online Arrange a meeting with your specialist in order to acquire all the data about medicine and take it legitimately. After meeting, you should be completely aware of your medication, and also be aware of the consumption of the medicine, which you can easily get from our online drugstore. Site name Pharmacy has been a pioneer in the field for giving its clients the incredible service and most reasonable costs available. Clinical Signs This medicine as any benzodiazepine medicate is utilized by the patients with intense conditions of nervousness, self-destructive propensities, uncontrolled fits of anxiety, social fears, and other mental disorders. Furthermore, dynamic elements of this drug may help you to stay calm, unwinding and sleep well, and calming impact without a moment’s delay just taking a short time remove flights and much more. Doses and administration As any radical cure this medicine should be utilized dependably. Try not to disregard safety measures regarding medicine and specialist’s suggestions. Avoid to take the overdose of the medicine and don’t disregard cooperative potency. Sedatives, torment executioners, narcotics and antihistamines are strengthened by Ativan while nicotine decreases Ativan’s movement. It is entirely taboo to join these pills with ethanol containing drinks. Any activity which needs extra focus should be deferred. The doses specified here is a normal, exact dose should be managed by your attending doctor. Doses are; 0.5mg to 1 mg, 2 or 3 times each day when you feel it compulsory. If you experience the ill effects of a sleeping disorder of any starting point take 0.5mg of the pill before sleep. Being beset with intense tension or fomentation the measurement is 2 – 3 pills for every day. Different Contraindications You should know etiology of your issue before starting of the treatment, Ativan is a Central Nervous System specialist, it controls lopsided chemicals in your cerebrum if your issue has genuine psychical mixes Lorazepam might be of, no utilization to you or even fall apart your current state. Aside from that, Ativan should be circumspectly taken by the patients with hepatic deficiency, respiratory issues, by the pregnant or nursing ladies or kids younger than 18. Symptoms or Side Effects In case of double dose or missed dose, These pills includes the side effects; day drowsiness, cerebral pain, dazedness, stomach inconvenience, loss of coordination, weakened memory and thinking capacities etc. Refraining from high-hazard work execution is exceedingly suggested. Your sharpness, focus, and consideration might be disabled at the time of prescription.   Contact US now for a good deal using any of the info below: Email: zerolakechem@gmsil.com Wickr Id: zerolakechem2021 Whatsapp: +(509) 255-8233 The most effective method to devour The Ativan doses rely on the seriousness of your signs and essential condition. Every patient should have an individual solution for the highest advantageous impacts. Keep your medication far from light, warmth, and dampness. We allow you to buy ativan online without prescription A large number of online pharmacies are working around the world. But, you can get this medicine at the discounted rate when you purchased Ativan from us. Site name has an extraordinary assortment of offers empowering the client to get Ativan at reduced costs. By picking Ativan generic tablets at the cheap rate, an individual can be guaranteed of saving, contrasted to branded Ativan, but the decision is yours. The cost of the tablets decreases through user’s driven plans which urge them to look for the medicinal items on a successive premise. The characteristic and the most well-known reason which empowers us to offer Ativan at the discounted rate is the direct purchase of the medicines from producers. The medicines are loaded in the store with the detailed description. Those instructions provide an information to the users about working dosage in the body. By ordering us, one can get medicine at a low rate and in best quality. We offer authorized Ativan tablets This online drugstore is offering genuine Ativan pills to individuals. Just when you take Approved pills it is workable for you to get enough impact on the state. Along these lines, you can guarantee yourself that you can get genuine Ativan tablets from us for your treatment. We source just from real medication makers so we additionally wind up in offering genuine medicines. While Ativan online buying is completely legal here. Security Guaranteed We provide the complete security to our users. Once you will make a purchase here, you’ll come to know that online buying from our drugstore is completely secure and beneficiary. Ativan’s precautionary measures during usage - If people have an intrinsic hypersensitivity to the medicine, the issue must be imparted already to the doctor. - The prescription, after the design is expert, the intake must be pulled back, but in a staged way. - The strike of intake of the tablet and the prescribed doses of Ativan should be done under the command of an accomplished doctor. Contact US now for a good deal using any of the info below: Email: zerolakechem@gmsil.com Wickr Id: zerolakechem2021 Whatsapp: +(509) 255-8233 Read the full article

[usnewsper-business]

Positive Earnings Reports Boost Stock Market: Analysts Optimistic #positiveearningsreports #stockmarketmovement

[stephenmccull]

Pfizer Court Fight Could Legalize Medicare Copays and Unleash ‘Gold Rush’ in Sales

Three years ago, pharma giant Pfizer paid $24 million to settle federal allegations that it was paying kickbacks and inflating sales by reimbursing Medicare patients for out-of-pocket medication costs.

By making prohibitively expensive medicine essentially free for patients, the company induced them to use Pfizer drugs even as the price of one of those medicines, covered by Medicare and Medicaid, soared 44% to $225,000 a year, the Justice Department alleged.

Now Pfizer is suing Uncle Sam to legalize essentially the same practice it was accused of three years ago — a fighting response to a federal crackdown that has resulted in a dozen drug companies being accused of similar practices.

A Pfizer win could cost taxpayers billions of dollars and erase an important control on pharma marketing after decades of regulatory erosion and soaring drug prices, say health policy analysts. A federal judge’s ruling is expected any day.

“If this is legal for Pfizer, Pfizer will not be the only pharmaceutical company to use this, and there will effectively be a gold rush,” government lawyer Jacob Lillywhite said in oral arguments last month.

Pfizer’s legal argument “is aggressive,” said Chris Robertson, a professor of health law at Boston University. “But I think they’ve got such a political tailwind behind them” because of pocketbook pain over prescription medicine — even though it’s caused by pharma manufacturers. Pfizer’s message, “‘We’re just trying to help people afford their drugs,’ is pretty attractive,” he said.

That’s not all that’s working in Pfizer’s favor. Courts and regulations have been moving pharma’s way since the Food and Drug Administration allowed limited TV drug ads in the 1980s. Other companies of all kinds also have gained free speech rights allowing aggressive marketing and political influence that would have been unthinkable decades ago, legal scholars say.

Among other court arguments, Pfizer initially claimed that current regulation violates its speech protections under the First Amendment, essentially saying it should be allowed to communicate freely with third-party charities to direct patient assistance.

“It’s infuriating to realize that, as outlandish as they seem, these types of claims are finding a good deal of traction before many courts,” said Michelle Mello, a professor of law and medicine at Stanford University. “Drug companies are surely aware that the judicial trend has been toward more expansive recognition of commercial speech rights.”

Pfizer’s lawsuit, in the Southern District of New York, seeks a judge’s permission to directly reimburse patient expenses for two of its heart-failure drugs each costing $225,000 a year. An outside administrator would use Pfizer contributions to cover Medicare copays, deductibles and coinsurance for those drugs, which otherwise would cost patients about $13,000 a year.

Letting pharma companies put money directly into patients’ pockets to pay for their own expensive medicines “does induce people to get a specific product” instead of shopping for a cheaper or more effective alternative, said Stacie Dusetzina, an associate professor of health policy at Vanderbilt University. “It’s kind of the definition of a kickback.”

Government rule-makers have warned against such payments since the launch of Medicare’s Part D drug benefit in 2006. Drug companies routinely help privately insured patients with cost sharing through coupons and other means, but private carriers can negotiate the overall price.

Because Congress gave Medicare no control over prescription drug prices, having patients share at least part of the cost is the only economic force guarding against unlimited price hikes and industry profits at taxpayer expense.

At the same time, however, regulators have allowed the industry to help patients with copays by routing money through outside charities — but only as long as the charities are “bona fide, independent” organizations that don’t match drugmaker money with specific drugs.

Several charities have blatantly violated that rule in recent years by colluding with pharma companies to subsidize particular drugs, the Justice Department has alleged. A dozen companies have paid more than $1 billion to settle allegations of kickback violations.

Pfizer set up an internal fund at one of the charities, the Patient Access Network Foundation, to cover patient costs for a heart arrhythmia drug at exactly the same time it was raising the wholesale cost from $220 to $317 for a package of 40 capsules, the Justice Department said. Pfizer referred Medicare patients who needed the drug to the PAN Foundation, the government said.

Under such arrangements, every $1 million channeled through a charity “has the potential to generate up to $21 m[illion] for the sponsor company, funded by the U.S. government,” Andrew Baum, a Citi pharma stock analyst, wrote in 2017.

Pfizer settled the case, saying it was not an admission of wrongdoing but resulted from its “desire to put this legal matter behind us.”

The PAN Foundation and three other charities also made deals to resolve allegations that they functioned as disallowed conduits for patient assistance for multiple pharma companies. One organization, the Virginia-based Caring Voice Coalition, shut down after government scrutiny.

PAN’s settlement did not mention the alleged Pfizer transactions. Those were described in the separate government deal with Pfizer.

The 2019 PAN agreement related to “legacy matters” and “did not involve any of PAN’s current operations or disease funds,” organization CEO Dan Klein said via a spokesperson. “Nonprofit patient assistance programs like PAN are necessary to help people access the critical medications they need to stay healthy.”

But legal troubles have hardly slowed the pharma-funded patient assistance business.

Four penalized nonprofits agreed to stop directing money to specific drugs, but they continue to accept hundreds of millions of dollars in pharma donations to indirectly cover copays and other patient drug costs, organization reports and IRS filings show. HHS regulators allow the practice because the drug companies are not involved in deciding which patients and which drugs are subsidized.

Donations to six pharma-funded patient assistance charities reached $1.8 billion in 2019, only slightly less than the year before, a KHN analysis of their IRS filings shows. That was nearly 50% higher than the amount from five years previously, before the Justice Department started cracking down.

Last year Pfizer donated $39.7 million to PAN and five other charities helping patients with out-of-pocket drug costs, company disclosures show.

If Pfizer’s lawsuit seeking to earmark such donations for its tafamidis heart-failure drugs opens the way for similar practices industrywide, it would drive up Medicare costs through rising prices and numbers of prescriptions, said Gerard Anderson, an economist and health policy professor at Johns Hopkins University’s Bloomberg School of Public Health. Such a program for tafamidis alone would increase Medicare costs by $30 billion, the Health and Human Services Department’s inspector general estimated.

Pharma companies can “learn which patients are using the drug, and they can market [and offer financial assistance] directly to that patient,” Anderson said. “You get a huge return.”

Pfizer argues that its proposal, which the HHS inspector general called “highly suspect” in an advisory opinion before the company filed its lawsuit, is legal and sensible.

“Providing copay assistance to middle-income patients who have been prescribed tafamidis is an efficient and equitable way to lower their out-of-pocket costs,” company spokesperson Steven Danehy said.

But the real affordability problem for patients is that tafamidis is too expensive, federal attorney Lillywhite said in court arguments last month. (HHS’ Office of Inspector General declined to comment.)

Pfizer has “priced itself out of the market,” he said. The company is seeking to “do something that’s unprecedented, to upend decades of settled law and agency guidance” to boost sales of “what is the most expensive cardiovascular drug ever launched in the United States.”

After the oral arguments, Pfizer dropped claims that HHS rules violate its free speech rights. Judge Mary Kay Vyskocil is considering only the company’s contention that a dedicated fund for tafamidis would not violate kickback prohibitions because, among other arguments, it is the doctor who decides to prescribe the drug and create revenue for Pfizer, not the patient getting the financial assistance.

But legal analysts still see the case as part of a broad movement toward deregulation and corporate rights.

A 1970s Supreme Court case, viewed as paving the way for an explosion of drug, lawyer and liquor ads as well as corporate campaign donations, was about speech rights for prescription drug sellers in Virginia. In 2011 the court found that the First Amendment allows data miners to buy and sell prescription records from pharmacies, provided the patients aren’t identified.

A year later, a federal appeals court cited speech protections when it overturned the conviction of a pharma sales rep who had been promoting a drug for uses not approved by the FDA.

Even if Pfizer loses its case, the climate may be ripe for similar challenges by other drugmakers, especially after the appointment of more than 200 federal judges by business-friendly President Donald Trump, legal scholars said.

The federal kickback law doesn’t mention copay assistance charities “and wasn’t designed with these programs in mind,” said Mello, of Stanford. Pfizer’s lawsuit “should be a loud, clanging call to Congress” to explicitly define drug assistance subsidies as illegal kickbacks, she said.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

USE OUR CONTENT

This story can be republished for free (details).

Pfizer Court Fight Could Legalize Medicare Copays and Unleash ‘Gold Rush’ in Sales published first on https://smartdrinkingweb.weebly.com/

[orbemnews]

Bankers, Please Return to Your Desks Manhattan calling Goldman Sachs has joined JPMorgan Chase in telling its bankers that it’s almost time to come back to the office. David Solomon, Goldman’s C.E.O., sent a memo to employees advising them to “make plans to be in a position to return to the office” by June 14 in the U.S. and June 21 in Britain. JPMorgan plans to open its offices on May 17 on a voluntary basis and require that workers return to their desks in rotations starting in July. Goldman and JPMorgan’s moves put pressure on other banks to put an end to remote work, several bankers told DealBook. While many thought they could work from home through the summer, some executives are keen to get employees back into the office sooner. (Retail branches have been open throughout the pandemic.) Other major banks aren’t expecting employees to return in meaningful numbers for several months: Citigroup expects to have about 30 percent of its North America-based employees back in the office by the end of the summer. Bank of America’s C.E.O., Brian Moynihan, said recently that a return to the office probably wouldn’t take place until after Labor Day. Wells Fargo said it was “optimistic” that workers would be able to return to the office on Sept. 6. These decisions may be complicated by where the banks’ offices are. It could be easier to coax workers back to JPMorgan’s headquarters in Midtown East, for example, than to Times Square, home to Barclays and Morgan Stanley, where businesses were especially hard-hit by the pandemic and a handful of highly publicized crimes have recently taken place. “People are so on edge and so uncertain about their own future that all these situations are exaggerated,” Kathryn Wylde, the president of the Partnership for New York City, told The Times. Jamie Dimon appears eager for the end of remote working. “I’m about to cancel all my Zoom meetings,” the JPMorgan chief said at an event hosted by The Wall Street Journal. Working from home “does not work for younger people, it doesn’t work for those who want to hustle, it doesn’t work in terms of spontaneous idea generation,” he noted. Dimon said his bank had lost some business because rivals had visited a potential client in person and JPMorgan’s bankers hadn’t. He acknowledged that there was some pushback on the bank’s plans, but didn’t seem willing to give in. “Yes, people don’t like commuting, but so what,” he said. In other Manhattan workplace moves, the New York Stock Exchange issued guidance that allows trading firms to increase their staff on the floor if the employees provide proof of vaccination. And the United Nations is taking a more cautious approach to reopening than its host city, saying that it was premature to plan for an in-person General Assembly in September. Even Eric Yuan, Zoom’s C.E.O., has Zoom fatigue. As a result, he has stopped scheduling back-to-back video chats. “I’m so tired of that,” he said. HERE’S WHAT’S HAPPENING Business groups oppose voting restrictions in Texas. A coalition including HP and Microsoft published a letter yesterday criticizing “any changes that would restrict eligible voters’ access to the ballot.” A second letter, signed by more than 100 Houston executives, criticized the Texas legislation as “voter suppression.” Both show how companies are more willing to wade into the debate over voting limits after Georgia enacted a bill with restrictions last month. More details emerge about the Gates divorce. Cascade Investment, a holding company owned by Bill Gates, transferred over $1.8 billion worth of assets to Melinda Gates on Monday, the day that the two announced their plans to split. And although they will retain their roles as co-chairs and trustees of the Gates Foundation, questions remain about whether they will focus more on their individual philanthropies after they divorce. The White House alters its Covid-19 vaccination strategy. The Biden administration will shift emphasis from mass inoculation sites to smaller ones like pharmacies to get more people in the U.S. vaccinated. Meanwhile, the campaign to vaccinate the world is floundering, with the virus spreading more rapidly than ever, driven by new waves in South America and India. Corporate America responds to India’s pandemic surge. The Global Task Force on Pandemic Response, organized by the Chamber of Commerce, Microsoft, IBM and Accenture, with support from the Business Roundtable, will organize assistance to the country. It will begin by sending 1,000 ventilators and 25,000 oxygen concentrators by the end of the month. Pfizer reveals how its Covid-19 vaccine has boosted its financials. The drugmaker said it had collected $3.5 billion in sales from the shot, likely equating to roughly $900 million in pretax profits. It plans to seek emergency approval to use the vaccine in children age 2 to 11 in September and full approval for use in adults this month. Janet Yellen states the obvious, and markets shudder Janet Yellen, the Treasury secretary and former Fed chair, got in a bit of a tangle yesterday. She rattled the markets at one event — then used her appearance at a second conference to clarify her remarks. Today in Business Updated  May 4, 2021, 6:53 p.m. ET “It may be that interest rates will have to rise somewhat to make sure that our economy doesn’t overheat,” she said at the first event, hosted by The Atlantic. Investors seized on those words — tech stocks tumbled most of all on the prospects of higher rates — and critics said she was improperly interfering in monetary policy. Fed officials have said that any spike in inflation linked to robust government spending and a postpandemic reopening is likely to be temporary; the central bank has pledged to keep interest rates low for a long time. “Let me be clear, it’s not something I’m predicting or recommending,” Yellen said at the second event, hosted by The Wall Street Journal, a few hours later. “If anybody appreciates the independence of the Fed, I think that person is me.” Indeed, when she was the Fed chair, Yellen had to deal with persistent jawboning from Donald Trump, who spoke out more explicitly about Fed policy than many previous presidents. Stocks pared their losses. “Markets were unhappy at this statement of the blindingly obvious,” Paul Donovan of UBS wrote in a note to clients today. He and other market watchers have noted that Yellen’s comments essentially described the mechanics of monetary policy and weren’t framed as a prediction. Still, her words carry extra weight, given her previous job. The brief freakout over the mere notion of higher interest rates also revealed how dependent the markets have become on extraordinarily easy monetary policy over the past year. “This trial is going to be a sprawling mess of irrelevant, prejudicial evidence.” — Amy Saharia, a lawyer for Elizabeth Holmes, the founder of Theranos, at her client’s first appearance in court over criminal fraud charges in more than a year. A federal prosecutor responded that Holmes “defrauded patients by saying tests were accurate and reliable when they weren’t — and she knew it.” Dogecoin does its thing Dogecoin, the cryptocurrency that started as a joke, is still on a tear, after another surge pushed it up a whopping 14,000 percent so far this year. One theory is that the upcoming appearance of Elon Musk, a noted Dogecoin superfan, as host of “Saturday Night Live” could get more people interested in trading the crypto token. (It’s as good a reason as any for those who try to rationalize its movements.) The latest bout of Dogecoin mania has overshadowed what’s going on in Ethereum, the second-largest cryptocurrency, which set records this week and made its 27-year-old co-creator, Vitalik Buterin, a billionaire (in dollars). Ethereum is up more than 350 percent for the year to date, outpacing Bitcoin’s relatively pedestrian 90 percent gain — which, for context, outpaces every stock in the S&P 500. Who decides Trump’s fate on Facebook At 9 a.m. Eastern today, the Facebook Oversight Board will announce whether it believes Facebook was justified in barring Donald Trump after he used the platform to incite a mob of supporters who attacked the Capitol on Jan. 6. Here’s what you need to know about what Mark Zuckerberg has called Facebook’s “Supreme Court,” whose decision could influence how all social networks treat political speech. What is the Facebook Oversight Board? Facebook assembled the board to vet its most sensitive decisions on moderating content. It consists of 20 members, including experts in human rights, constitutional law and journalism. The board’s cases, which are referred by Facebook or the public, are reviewed by a panel of five members, who consider whether the company’s decision is consistent with its rules and human rights laws. A majority of the full board must approve the final decision. Does the board have any power? Only what Facebook gives it. The company has said it will abide by the board’s rulings, and the board’s charter emphasizes its independence. But Facebook has no legal obligation to follow those decisions, and it funds the organization through a $130 million trust. What exactly will the board decide in this case? It could vote to reinstate Trump’s Facebook account or uphold the ban. Or it could provide a ruling with more nuance, such as finding that the ban was appropriate at the time it was initiated but is no longer necessary. In addition to a ruling in this case, Facebook has asked for broader policy recommendations. “Basically the board is setting the tone here for what they’re going to do going forward — how much power they’re going to have, how much power they’re not going to have, whether they’re even going to be constrained by how the question was posed to them with Facebook,” Kate Klonick, an assistant professor of law at St. John’s University, told NPR. THE SPEED READ Deals Tiger Global, the big tech investment firm, reportedly plans to raise $10 billion for its next fund. (FT) Listing news roundup: Jessica Alba’s Honest Company raised $413 million in its I.P.O. at a $1.5 billion valuation; JAB’s Krispy Kreme filed confidentially to go public; and the Equinox gym chain is reportedly in talks to merge with a SPAC founded by Chamath Palihapitiya. (Bloomberg) Politics and policy How two Black C.E.O.s got corporate America to pay attention to voting rights. (WaPo) U.S. officials are pushing Taiwanese chip makers to prioritize American automakers’ demands to ease supply shortages. (Reuters) Inside the debate about who would actually pay President Biden’s corporate tax increase. (WSJ) Tech China is building electric car plants nearly as fast as Europe and the U.S. combined. (NYT) The privacy-focused messaging app Signal said Facebook had blocked it from buying Instagram ads about the social network’s user-data gathering practices. (Insider) Best of the rest A majority of G.E. shareholders voted to reject a $230 million compensation package for the company’s C.E.O., Larry Culp. (FT) Pandora, the world’s largest jewelry maker, is abandoning mined diamonds for lab-created ones. (NYT) We’d like your feedback! Please email thoughts and suggestions to dealbook@nytimes.com. Source link Orbem News #bankers #desks #return